# OnCo record nct06428019 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06428019/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06428019", "NCT06428019" ;
  schema:name "A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)"@en ;
  schema:description "A phase 3 trial of Venetoclax, Acalabrutinib and Obinutuzumab in chronic lymphocytic leukaemia, run by AbbVie, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06428019/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06428019> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2024-08-05" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/cll-treatment-naive/> ;
  onco:technologies <https://onco.cc/technologies/bcl2-inhibitors/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/obinutuzumab/> ;
  onco:companies <https://onco.cc/companies/abbvie/> .